Scarica l'app Stockscreener
65.85
1.19%
0.8081
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$65.04
Aprire:
$65.98
Volume 24 ore:
61,880
Relative Volume:
0.05
Capitalizzazione di mercato:
$5.45B
Reddito:
$1.73B
Utile/perdita netta:
$682.64M
Rapporto P/E:
8.5115
EPS:
7.7364
Flusso di cassa netto:
$411.18M
1 W Prestazione:
+1.96%
1M Prestazione:
-4.48%
6M Prestazione:
-9.33%
1 anno Prestazione:
+81.86%
Intervallo 1D:
$65.52
$66.34
Intervallo di 1 settimana:
$63.18
$67.34
Portata 52W:
$37.94
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
65.79 | 5.39B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
426.82 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.93 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.09 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.37 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.08 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-01 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
PTC Therapeutics stock sinks as pivotal data fails to calm sellers - MSN
Assessing PTC Therapeutics (PTCT) Valuation After Encouraging New Huntington’s Disease Data - Yahoo Finance
Horizon Investments LLC Takes $3.06 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The PTC Therapeutics (PTCT) Story Is Shifting With Sephience And Franchise Pressures - Yahoo Finance
Three PTC investor conference webcasts start May 12 and stay up 30 days - Stock Titan
Vanguard Group Inc. Purchases 514,204 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
UBS Group AG Has $73.28 Million Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
(PTCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Hussman Strategic Advisors Inc. Has $1.91 Million Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Reports Positive Huntington’s Disease Trial Results - Insider Monkey
Is PTC Therapeutics a Better Buy Than Eli Lilly? - Trefis
PTC Therapeutics Hits Day Low of $63.76 Amid Price Pressure - Markets Mojo
MSN Money - MSN
PTC Therapeutics (PTCT) Is Down 5.1% After New Votoplam Huntington’s Data And Novartis Milestone - Yahoo Finance
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers - Sahm
Vanguard holds 4.28M PTC Therapeutics (NASDAQ: PTCT) shares - Stock Titan
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com
Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com
PTC Therapeutics (PTCT) Expected to Announce Earnings on Thursday - MarketBeat
PTC Therapeutics Stock To $84? - Trefis
Is 12.3% Fall In PTC Therapeutics (PTCT) Stock A Buying Opportunity? - Trefis
PTC Therapeutics Drops 8.3% Amid Sector-Wide Selling - AlphaStreet
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's DiseaseSlideshow (NASDAQ:PTCT) 2026-04-29 - Seeking Alpha
Vanguard (NASDAQ: PTCT) holds 4.87M PTC Therapeutics shares - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.5%Here's What Happened - MarketBeat
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $93 - Moomoo
AA meeting of minds as PTC, Novartis push votoplam in HD - BioWorld News
Is PTC Therapeutics (PTCT) Pricing Reflect Recent Pipeline Progress And Volatile Share Performance - simplywall.st
PTC Therapeutics, Inc. $PTCT Shares Sold by Pictet Asset Management Holding SA - MarketBeat
M&T Bank Corp Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington’s Slowing Signals - MarketBeat
PTCT: Promising Results in Huntington's Disease Treatment Study - GuruFocus
PTC Therapeutics : PIVOT-HD Long-Term Extension Study Topline Results Call – April 28, 2026 - marketscreener.com
PTC Therapeutics Reports Positive 24-Month Votoplam Data - TipRanks
PTC Therapeutics (NASDAQ: PTCT) shows 52% slowing in HD study - Stock Titan
PTC reports votoplam slowed Huntington’s disease progression by 52% - Investing.com Canada
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam - ChartMill
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study - ChartMill
Teachers Retirement System of The State of Kentucky Buys 19,000 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
Huntington’s Disease Pipeline Set for Breakthrough Transformation by 2026 with 20+ Therapies and Advancing Gene-Silencing Innovations | DelveInsight - Barchart.com
PTC Therapeutics Inc (PTCT) - MSN
Q3 2025 PTC Therapeutics Inc Earnings Call Transcript - GuruFocus
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics, Inc. $PTCT Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
Assessing PTC Therapeutics (PTCT) Valuation After Recent Share Price Swings And Pipeline Progress - Sahm
Roche gets EU nod for Evrysdi's expanded label in spinal muscular atrophy - MSN
PTC Therapeutics Shares Drop After FDA Rejects Vatiquinone Application - MSN
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Nasdaq
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):